Literature DB >> 15255129

Rapid improvement of acute pulmonary edema with angiotensin converting enzyme inhibitor under hemodialysis in a patient with renovascular disease.

Yoshihide Fujigaki1, Akashi Togawa, Takehiko Miyaji, Hiroyuki Suzuki, Naro Ohashi, Hirotaka Fukasawa, Hideo Yasuda, Tatsuo Yamamoto, Akira Hishida, Katsuhiko Yonemura.   

Abstract

A 71-year-old man with bilateral renovascular disease was admitted to Hamamatsu University hospital because of appetite loss and acute shortness of breath due to acute pulmonary edema (APE) with accelerated hypertension and renal failure. Hypertension and APE were controlled by an angiotensin converting enzyme inhibitor (ACEI) and four sessions of hemodialysis with reduction of 1.8 kg bodyweight. Renal function was later stabilized and the patient required no ACEI or hemodialysis. A trial of right renal angioplasty 1 month after admission failed and renal function deteriorated (serum creatinine 7.1 mg/dL) with accelerated hypertension, gain of bodyweight and APE. Even after four sessions of hemodialysis with adequate reduction of bodyweight, APE was not controlled, but it rapidly improved after administration of an ACEI, without major bodyweight change. As no apparent cardiac dysfunction was evident, APE might have been caused by a direct action of angiotensin II on hyperpermeability in pulmonary capillaries. Blocking of angiotensin II should be considered in such patients even after introduction of hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255129     DOI: 10.1111/j.1526-0968.2003.00124.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  1 in total

1.  Percutaneous Transluminal Revascularization following an Angiotensin Receptor Blocker: Successful Treatment for Flash Pulmonary Edema and Hyponatremic Hypertensive Syndrome.

Authors:  Leping Shao; Yanxia Gao; Yan Xu; Yanhua Lang
Journal:  Cardiorenal Med       Date:  2012-06-14       Impact factor: 2.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.